nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Due to the COVID-19 pandemic, the global Insulin Glargine market size is estimated to be worth US$ 6461 million in 2021 and is forecast to a readjusted size of US$ 8487.8 million by 2028 with a CAGR of 4.0% during the review period. Fully considering the economic change by this health crisis, the Europe Insulin Glargine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Insulin Glargine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Global Insulin Glargine key players include Sanofi, Eli Lilly, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
This report focuses on Insulin Glargine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Insulin Glargine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India, etc.
Global Insulin Glargine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Prefilled Injection
Non-Prefilled Injection
Segment by Application
Type 1 Diabetes Treatment
Type 2 Diabetes Treatment
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Sanofi
Eli Lilly
Viatris
Gan&Lee Pharmaceuticals
Tonghua Dongbao Pharmaceutical
United Laboratories International